Pacira Q1 rev $158M (+33% YoY), net income $6.8M, appoints COO

Pacira BioSciences, Inc.

2022-Q1 EPS reported $0.15 revenue$157,991,000

Q1 revenue $158.0M (+33% YoY); EXPAREL $129.2M, ZILRETTA $23.6M (acquired Nov 2021).
GAAP net income $6.8M ($0.15/sh); non-GAAP net income $29.9M ($0.67 basic).
Adjusted EBITDA $53.8M ($1.16/diluted sh) vs $36.2M in Q1 2021.
Daryl Gaugler appointed COO effective May 4, 2022; was SVP Commercial Ops.
No revenue guidance due to COVID uncertainty; reiterates FY2022 opex guidance.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Daryl Gaugler

Chief Operating Officer

PCRX · Pacira BioSciences, Inc.

Effective: 2022-05-04
Filed: May 4, 2022, 7:59 PM ET

On May 4, 2022, Daryl Gaugler, the current Senior Vice President, Commercial Operations of the Company, was promoted to Chief Operating Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Daryl Gaugler changed role as Chief Operating Officer at Pacira BioSciences, Inc..

Action: promoted
Role: Chief Operating Officer

Exact text from the filing

On May 4, 2022, Daryl Gaugler, the current Senior Vice President, Commercial Operations of the Company, was promoted to Chief Operating Officer, effective immediately.

View on SEC.gov

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-22-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.